Manferdelli, Giorgio, Marc M. Berger, and Andrew M. Luks. Ignoble gas: The questionable role of xenon in rapid ascents of Mount Everest. High Alt Med Biol. 26:339–346, 2025.—Beyond the logistical, technical, and physiological challenges associated with climbing extremely high mountains such as Mount Everest, an important feature of such expeditions is their long duration. Among the strategies used in recent years to reduce expedition duration, one particularly novel approach was implemented during Everest expeditions in 2024 and 2025—inhalation of the noble gas xenon prior to the expeditions. Despite the tremendous attention this approach received in the media, significant questions remain as to whether it is truly effective at improving acclimatization and shortening the duration of expeditions. This review examines this issue in greater detail. After providing background information on xenon, the review examines potential rationales for xenon’s use in the mountains, assesses the risks of xenon administration, and considers other aspects of the expedition protocol that likely affected the odds of summit success. Based on this analysis, there is no basis for widespread implementation of xenon inhalation at this time. Evidence of benefit is lacking, and there are strong reasons to believe other aspects of the expedition protocol contributed significantly to the expeditions’ outcomes. Much further research on these questions is warranted before any more climbers should engage in this potentially risky practice.
AinsliePN, SubudhiAW. Cerebral blood flow at high altitude. High Alt Med Biol, 2014; 15(2):133–140.
2.
Al TmimiL, Van HemelrijckJ, Van de VeldeM, et al.Xenon anaesthesia for patients undergoing off-pump coronary artery bypass graft surgery: A prospective randomized controlled pilot trial. Br J Anaesth, 2015; 115(4):550–559.
3.
ArnetteA. Everest by the Numbers: 2025 Edition; Everest Publishers; 2025.
4.
BaileyDM, BartschP, KnauthM, et al.Emerging concepts in acute mountain sickness and high-altitude cerebral edema: From the molecular to the morphological. Cell Mol Life Sci, 2009; 66(22):3583–3594.
5.
BantelC, MazeM, TrappS. Noble gas xenon is a novel adenosine triphosphate-sensitive potassium channel opener. Anesthesiology, 2010; 112(3):623–630.
6.
BaumertJH, HeckerKE, HeinM, et al.Effects of xenon anaesthesia on the circulatory response to hypoventilation. Br J Anaesth, 2005; 95(2):166–171.
7.
BergerMM, SchieferLM, TreffG, et al.Acute high-altitude illness: Updated principles of pathophysiology, prevention, and treatment. Dtsch Z Sportmed, 2020; 71(11–12):267–274.
8.
BogageJ. (2019). A Mount Everest climb often takes two months. A California climber just did it in two weeks. In The Washington Post.
9.
BreuerT, EmontzpohlC, CoburnM, et al.Xenon triggers pro-inflammatory effects and suppresses the anti-inflammatory response compared to sevoflurane in patients undergoing cardiac surgery. Crit Care, 2015; 19:365.
10.
BrocherieF, MilletGP, D’HulstG, et al.Repeated maximal-intensity hypoxic exercise superimposed to hypoxic residence boosts skeletal muscle transcriptional responses in elite team-sport athletes. Acta Physiol (Oxf), 2018; 222.
11.
BurtscherM. Xenon - Propelling climbers to the summits of the world’s highest mountains? N Engl J Med, 2025; 393:615–616.
12.
CarnsA, StazickerA. Two Special Forces Legends in Death Zone: Alistair Carns & Staz. WoodallD, ed., YouTube; 2025.
13.
CoburnM, BaumertJH, RoertgenD, et al.Emergence and early cognitive function in the elderly after xenon or desflurane anaesthesia: A double-blinded randomized controlled trial. Br J Anaesth, 2007; 98:756–762.
14.
CullenSC, EgerEI2nd, CullenBF, et al.Observations on the anesthetic effect of the combination of xenon and halothane. Anesthesiology, 1969; 31:305–309.
15.
CullenSC, GrossEG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science (1979), 1951; 113:580–582.
16.
de SousaSL, DickinsonR, LiebWR, et al.Contrasting synaptic actions of the inhalational general anesthetics isoflurane and xenon. Anesthesiology, 2000; 92:1055–1066.
17.
DehnertC, BergerMM, MairbaurlH, et al.High altitude pulmonary edema: A pressure-induced leak. Respir Physiol Neurobiol, 2007; 158:266–273.
18.
DehnertC, BohmA, GrigorievI, et al.Sleeping in moderate hypoxia at home for prevention of acute mountain sickness (AMS): A placebo-controlled, randomized double-blind study. Wilderness Environ Med, 2014; 25:263–271.
19.
DiasKA, LawleyJS, GattererH, et al.Effect of acute and chronic xenon inhalation on erythropoietin, hematological parameters, and athletic performance. J Appl Physiol (1985), 2019; 127:1503–1510.
20.
FinkH, BlobnerM, BogdanskiR, et al.Effects of xenon on cerebral blood flow and autoregulation: An experimental study in pigs. Br J Anaesth, 2000; 84:221–225.
21.
FrancisRC, HohneC, KleinA, et al.Endothelin-a receptor blockade does not debilitate the cardiovascular and hormonal adaptation to xenon or isoflurane anesthesia in dogs. Exp Biol Med (Maywood), 2006; 231:834–839.
22.
FrancisRC, Reyle-HahnMS, HohneC, et al.The haemodynamic and catecholamine response to xenon/remifentanil anaesthesia in Beagle dogs. Lab Anim, 2008; 42:338–349.
23.
FriesM, NolteKW, CoburnM, et al.Xenon reduces neurohistopathological damage and improves the early neurological deficit after cardiac arrest in pigs. Crit Care Med, 2008; 36(8):2420–2426.
24.
FrietschT, BogdanskiR, BlobnerM, et al.Effects of xenon on cerebral blood flow and cerebral glucose utilization in rats. Anesthesiology, 2001; 94(2):290–297.
25.
FulcoCS, MuzaSR, BeidlemanBA, et al.Effect of repeated normobaric hypoxia exposures during sleep on acute mountain sickness, exercise performance, and sleep during exposure to terrestrial altitude. Am J Physiol Regul Integr Comp Physiol, 2011; 300(2):R428–R436.
26.
GoetzenichA, HatamN, PreussS, et al.The role of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in late-phase preconditioning with xenon, isoflurane and levosimendan in rat cardiomyocytes. Interact Cardiovasc Thorac Surg, 2014; 18(3):321–328.
27.
GrussM, BushellTJ, BrightDP, et al.Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol, 2004; 65(2):443–452.
28.
GurD, YonasH, JacksonDL, et al.Measurement of cerebral blood flow during xenon inhalation as measured by the microspheres method. Stroke, 1985; 16(5):871–874.
29.
HarringtonE. Emily Harrington on her rapid ascent of Cho Oyu. UKClimbing, 2016.
30.
HartmannA, DettmersC, SchuierFJ, et al.Effect of stable xenon on regional cerebral blood flow and the electroencephalogram in normal volunteers. Stroke, 1991; 22(2):182–189.
31.
HeinM, BaumertJH, RoehlAB, et al.Xenon alters right ventricular function. Acta Anaesthesiol Scand, 2008; 52(8):1056–1063.
32.
HiltyMP, HeftiU, BouzatP, et al.Xenon inhalation for expeditions to high altitude: A position statement from the international climbing and mountaineering federation (Union Internationale des Associations d’Alpinisme, UIAA) medical commission. High Alt Med Biol, 2025.
33.
Himalayan Database. The Expedition Archives of Elizabeth Hawley. ClubTAA., ed. Adventures F. Everest South Flash; 2004.
34.
HollK, NematiN, KohmuraE, et al.Stable-xenon-CT: Effects of xenon inhalation on EEG and cardio-respiratory parameters in the human. Acta Neurochir (Wien), 1987a;87(3–4):129–133.
35.
HollK, SamiiM, GaabMR, et al.EEG changes during five minutes of inhalation of a 33% xenon-O2 mixture. Neurosurg Rev, 1987b;10(4):309–310.
36.
JinZ, PiazzaO, MaD, et al.Xenon anesthesia and beyond: Pros and cons. Minerva Anestesiol, 2019; 85(1):83–89.
37.
KariJS, HueyRB. Size and seasonal temperature in open-access-ranging Drosophila subobscura. J Therm Biol, 2000; 25(4):267–272.
38.
LaitioRM, KaistiKK, LaangsjoJW, et al.Effects of xenon anesthesia on cerebral blood flow in humans: A positron emission tomography study. Anesthesiology, 2007; 106(6):1128–1133.
39.
LawLS, LoEA, GanTJ. Xenon anesthesia: A systematic review and meta-analysis of randomized controlled trials. Anesth Analg, 2016; 122(3):678–697.
40.
LawleyJS, GattererH, DiasKA, et al.Safety, hemodynamic effects, and detection of acute xenon inhalation: Rationale for banning xenon from sport. J Appl Physiol (1985), 2019; 127(6):1511–1518.
41.
LiangM, AhmadF, DickinsonR. Neuroprotection by the noble gases argon and xenon as treatments for acquired brain injury: A preclinical systematic review and meta-analysis. Br J Anaesth, 2022; 129(2):200–218.
42.
LimatolaV, WardP, CattanoD, et al.Xenon preconditioning confers neuroprotection regardless of gender in a mouse model of transient middle cerebral artery occlusion. Neuroscience, 2010; 165(3):874–881.
43.
LoEA, LawLS, GanTJ. Paradox of the incidence of postoperative nausea and vomiting after xenon-based anaesthesia. Br J Anaesth, 2016; 116(6):881–883.
44.
LuksAM, AinsliePN, LawleyJS, et al.Acute mountain sickness. In Ward, Milledge and West’s High Altitude Medicine and Physiology. Taylor & Franciss Group: Boca Raton, FL; 2021a.
45.
LuksAM, AinsliePN, LawleyJS, et al.High altitiude cerebral edema. In Ward, Milledge and West’s High Altitude Medicine and Physiology. Taylor & Franciss Group: Boca Raton, FL; 2021b.
46.
LuksAM. Physiology in medicine: A physiologic approach to prevention and treatment of acute high altitude illnesses. J Appl Physiol (1985), 2015; 118(5):509–519.
47.
LundbyC, RobachP, BoushelR, et al.Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport? J Appl Physiol (1985), 2008; 105(2):581–587.
48.
LuttroppHH, RomnerB, PerhagL, et al.Left ventricular performance and cerebral haemodynamics during xenon anaesthesia. A transoesophageal echocardiography and transcranial Doppler sonography study. Anaesthesia, 1993; 48(12):1045–1049.
49.
MaD, LimT, XuJ, et al.Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol, 2009; 20(4):713–720.
50.
ManferdelliG, MarzoratiM, EastonC, et al.Changes in prefrontal cerebral oxygenation and microvascular blood volume in hypoxia and possible association with acute mountain sickness. Exp Physiol, 2021; 106(1):76–85.
51.
MazeM, LaitioT. Neuroprotective properties of xenon. Mol Neurobiol, 2020; 57(1):118–124.
52.
McGuiganS, MarieDJ, O’BryanLJ, et al.The cellular mechanisms associated with the anesthetic and neuroprotective properties of xenon: A systematic review of the preclinical literature. Front Neurosci, 2023; 17:1225191.
53.
MilletGP, JornetK. On top to the top-acclimatization strategy for the “fastest known time” to Mount Everest. Int J Sports Physiol Perform, 2019; 14:1438–1441.
54.
NairAS, ChristopherA, PulipakaSK, et al.Efficacy of xenon anesthesia in preventing postoperative cognitive dysfunction after cardiac and major non-cardiac surgeries in elderly patients: A topical review. Med Gas Res, 2021; 11(3):110–113.
55.
NeukirchenM, HippJ, SchaeferMS, et al.Cardiovascular stability and unchanged muscle sympathetic activity during xenon anaesthesia: Role of norepinephrine uptake inhibition. Br J Anaesth, 2012; 109(6):887–896.
56.
PagliaroP, WeberNC, FemminoS, et al.Gasotransmitters and noble gases in cardioprotection: Unraveling molecular pathways for future therapeutic strategies. Basic Res Cardiol, 2024; 119(4):509–544.
57.
PainCF, GlazierJB, SimonH, et al.Regional and overall inequality of ventilation and blood flow in patients with chronic airflow obstruction. Thorax, 1967; 22(5):453–461.
58.
PlougmannJ, AstrupJ, PedersenJ, et al.Effect of stable xenon inhalation on intracranial pressure during measurement of cerebral blood flow in head injury. J Neurosurg, 1994; 81(6):822–828.
59.
RamsayW, TraversMW. On a new constituent of atmospheric air. Proc. R. Soc. Lond, 1898; 63:405–408.
60.
SartoriC, AllemannY, ScherrerU. Pathogenesis of pulmonary edema: Learning from high-altitude pulmonary edema. Respir Physiol Neurobiol, 2007; 159(3):338–349.
61.
SchaeferMS, PiperT, GeyerH, et al.Xenon elimination kinetics following brief exposure. Drug Test Anal, 2017; 9(5):666–670.
62.
SchaeferW, MeyerPT, RossaintR, et al.Myocardial blood flow during general anesthesia with xenon in humans: A positron emission tomography study. Anesthesiology, 2011; 114(6):1373–1379.
63.
SchobersbergerB. Flash - der neue Expeditionsstil mit Zukunft? Die praxisorientierte Seite. In Alpinmedizinischer. Rundbrief; 2019. pp. 16–21.
64.
SimicevicV. When Climbing the World’s Tallest Mountains. What Counts as Cheating? In National Geographic, 2025.
65.
StoppeC, NeyJ, BrenkeM, et al.Sub-anesthetic xenon increases erythropoietin levels in humans: A randomized controlled trial. Sports Med, 2016; 46(11):1753–1766.
66.
StoppeC, NeyJ, BrenkeM, et al.Correction to: Sub-anesthetic xenon increases erythropoietin levels in humans: A randomized controlled trial. Sports Med, 2018; 48(3):751.
67.
SuttonJR, ReevesJT, WagnerPD, et al.Operation Everest II: Oxygen transport during exercise at extreme simulated altitude. J Appl Physiol (1985), 1988; 64(4):1309–1321.
TasselC, Le DareB, MorelI, et al.[Xenon: From rare gaz to doping product]. Presse Med, 2016; 45(4 Pt 1):422–430.
71.
ThomsenJJ, RentschRL, RobachP, et al.Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity. Eur J Appl Physiol, 2007; 101(4):481–486.
72.
Tissot van PatotMC, LeadbetterG, KeyesLE, et al.Greater open-access plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol (1985), 2005; 98(5):1626–1629.
73.
Van HeseL, Al TmimiL, DevroeS, et al.Neuroprotective properties of xenon in different types of CNS injury. Br J Anaesth, 2018; 121(6):1365–1368.
74.
WakehamDJ, TomlinsonAR, HackettPH, et al.The effects of stepwise reductions in supplemental oxygen on oxygen saturation at rest and during exercise at extreme (simulated) altitude. In International Hypoxia Symposia. Wiley: Lake Louise, Alberta. Canada; 2023.
75.
WapplerF, RossaintR, BaumertJ, et al.; Xenon Multicenter Study Research G. Multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery. Anesthesiology, 2007; 106(3):463–471.
76.
WilsonMH, EdsellME, DavagnanamI, et al.; Caudwell Xtreme Everest Research Group. Cerebral artery dilatation maintains cerebral oxygenation at extreme altitude and in acute hypoxia–an ultrasound and MRI study. J Cereb Blood Flow Metab, 2011; 31(10):2019–2029.
77.
WolfeJ, SharmaB. Up Everest in a Flash, Assisted by Xenon Gas. In The New York Times. The New York Times Company: New York; 2025. p. 26.
78.
YagiM, MashimoT, KawaguchiT, et al.Analgesic and hypnotic effects of subanaesthetic concentrations of xenon in human volunteers: Comparison with nitrous oxide. Br J Anaesth, 1995; 74:670–673.
79.
YangSR, HuaKF, ChuLJ, et al.Xenon blunts NF-kappaB/NLRP3 inflammasome activation and improves acute onset of accelerated and severe lupus nephritis in mice. Kidney Int, 2020; 98(2):378–390.
80.
YaoL, NemotoEM, BostonJR, et al.Effect of 80% Xe on whole brain blood flow and metabolism in awake monkeys. J Neurosurg Anesthesiol, 1992a;4(4):268–271.
81.
YaoLP, BandresJ, NemotoEM, et al.Effect of 33% xenon inhalation on whole-brain blood flow and metabolism in awake and fentanyl-anesthetized monkeys. Stroke, 1992b;23(1):69–74.
82.
YonasH, GrundyB, GurD, et al.Side effects of xenon inhalation. J Comput Assist Tomogr, 1981; 5(4):591–592.
83.
YonasH, GurD, GoodBC, et al.Stable xenon CT blood flow mapping for evaluation of patients with extracranial-intracranial bypass surgery. J Neurosurg, 1985; 62(3):324–333.
84.
ZardiniP, WestJB. Topographical distribution of ventilation in isolated lung. J Appl Physiol, 1966; 21(3):794–802.
85.
ZhangM, ChengY, ZhaiY, et al.Attenuated iron stress and oxidative stress may participate in anti-seizure and neuroprotective roles of xenon in pentylenetetrazole-induced epileptogenesis. Front Cell Neurosci, 2022; 16:1007458.
86.
ZhaoH, HuangH, OlogundeR, et al.Xenon treatment protects against remote lung injury after kidney transplantation in rats. Anesthesiology, 2015; 122(6):1312–1326.
87.
ZhaoH, LuoX, ZhouZ, et al.Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats. Kidney Int, 2014; 85(1):112–123.
